Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
U.S. Wide-Moat Stocks On Sale - The April 2023 Heat Map
03:09am, Wednesday, 05'th Apr 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.
7 Blue-Chip Stocks Sitting in the Sweet Spot
01:56pm, Thursday, 23'rd Mar 2023
Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won't do it any favors, specific stalwarts can get the business done. In
Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA
12:13pm, Thursday, 23'rd Mar 2023
The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen.
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
09:25am, Thursday, 23'rd Mar 2023
Ionis stock jumped Thursday after an FDA panel offered a mixed view of its Biogen-partnered drug for ALS. The post Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement appeared first on Inv
FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease
06:55pm, Wednesday, 22'nd Mar 2023
FDA advisors voted against the effectiveness of Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.
Biogen ALS drug considered not effective by FDA advisory panel
06:27pm, Wednesday, 22'nd Mar 2023
Biogen Inc. BIIB, -1.85% received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker's proposed amyotrophic lateral sclerosis, or ALS, treatme
FDA advisors reject Biogen's ALS drug for rare and aggressive form of the disease
05:36pm, Wednesday, 22'nd Mar 2023
FDA advisors voted against Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
04:13pm, Tuesday, 21'st Mar 2023
Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation.
Wall Street predicts approval for another ALS drug
11:45am, Tuesday, 21'st Mar 2023
It appears likely that a new drug to treat amyotrophic lateral sclerosis (ALS) will get approval in the U.S. Regulators shared their thinking ahead of an advisory committee meeting.
FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease
02:53pm, Monday, 20'th Mar 2023
The FDA staff on Monday said Biogen's investigational ALS drug tofersen may have a "clinical benefit" on a rare and aggressive form of the disease.
Should You Buy Biogen Before a Big July Decision?
05:30am, Sunday, 19'th Mar 2023
Biogen's blockbuster drugs are losing exclusivity -- and that's weighing on earnings. The company now is counting on its latest Alzheimer's drug to turn things around.
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
09:56am, Thursday, 16'th Mar 2023
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive
1 Reason to Buy Biogen Stock, and 1 Reason to Sell
10:23am, Tuesday, 14'th Mar 2023
Biogen recently won U.S. approval for an important Alzheimer's disease therapy. However, this medicine still faces some concerning headwinds in the market.
U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map
03:09am, Wednesday, 08'th Mar 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.
Biogen Should Resume Strong Growth With Zuranolone Approval
02:47am, Tuesday, 07'th Mar 2023
Biogen Q4 revenue was down 7% y/y. Zuranolone is a breakthrough depression therapy with an August 5, 2023, PDUFA date.
